INTERIM REPORT Q2, 2026

Sustained commercial momentum with 62% sales increase year-over-year and EMA filing to potentially double addressable market

Significant events

APRIL-JUNE

- Preclinical data on novel NK-Cell engager presented at the AACR Annual Meeting 2026
- Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment
- COMy: New clinical and real-world evidence for Pepaxti
- Oncopeptides receives formal approval from Norwegian authorities to initiate Window-of-Opportunity study in glioblastoma
- Study confirms use of Pepaxti for patients with reduced kidney function
- Oncopeptides signs agreement with Salus for Pepaxti in Central and Eastern Europe
- Oncopeptides presented clinical and translational data at EHA 2026 in Stockholm
- First patient recruited in Oncopeptides real-world-evidence study MARINA in Germany
- Oncopeptides submits Type II variation application to EMA
- First patient recruited in Oncopeptides' glioblastoma study

Events after the period

- Oncopeptides receives list price for Pepaxti in Slovenia, marking first expansion milestone in Central and Eastern Europe

Financial overview

APRIL-JUNE

- **Net sales** amounted to SEK 31.1 (19.2) million
- **Operating profit** amounted to SEK -48.7 (-56.2) million
- **Profit after tax** amounted to SEK -54.7 (-62.8) million
- **Earnings per share**, before and after dilution -0.14 (-0.30) SEK
- **Cash and cash equivalents** at the end of the period amounted to SEK 157.6 (70.1) million

Selected Key Indicators

(SEK thousand)	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2025 Jan-Dec
Net sales	31 099	19 183	56 483	32 449	71 118
Operating profit	-48 668	-56 233	-86 199	-116 069	-224 651
Profit after tax	-54 712	-62 849	-86 897	-123 518	-249 585
Earnings per share before and after dilution (SEK)	-0,14	-0,30	-0,27	-0,58	-1,10
Cash flow from operating activities	-42 811	-54 411	-88 403	-122 728	-216 493
Cash at the end of the period	157 614	70 146	157 614	70 146	82 255

CEO Statement

Oncopeptides continued its strong trajectory in Q2 2026, delivering net sales of SEK 31.1 million, a 62 percent increase compared to Q2 2025. Net sales for the first half of the year reached SEK 56.5 million, up 74 compared to the first half of 2025. Backed by a cash position of SEK 157.6 million, we remain on track toward achieving positive cash flow during 2027.

In Germany, our sharpened business model moves us steadily toward country-level profitability for the full year. The German MARINA real-world evidence study recruited the first patient. The study is an important scientific collaboration to deepen our understanding of clinical experience with a focus on the office-based setting. Italy continues to perform well above initial expectations, and we have actively managed market dynamics in Spain to regain sales momentum, with June reaching all-time high. More than 1,000 patients have now been treated with Pepaxti since launch.

In May, we signed an important distribution agreement with Salus Group, a leading pharmaceutical partner in Central and Eastern Europe (CEE). Covering 11 countries and addressing an estimated market potential of approx. SEK 150 million, this collaboration enables us to unlock regional demand significantly earlier than originally planned in a highly capital-efficient manner. Slovenia recently granted a list price, marking the first expansion milestone for the CEE region.

Partnerships will continue to grow in importance as we expand our geographic footprint. Collaborating with partners provides a flexible and efficient way to broaden access to our drug, ensuring both patient and shareholder value. In Japan, we continue our active engagement with potential partners including remote and in-person meetings during Q2 and Q3.

Another key milestone during the second quarter was the formal submission of our Type II variation application to the European Medicines Agency (EMA) to expand Pepaxti's indication into third-line multiple myeloma. Moving from our current fourth-line, triple-class refractory label into the third-line setting could create a powerful clinical and commercial multiplier effect for Oncopeptides, potentially doubling our addressable European patient population and the average number of treatment cycles per patient. We anticipate receiving a CHMP opinion between September-November 2026.

In June we welcomed the global hematology community to Stockholm for the European Hematology Association (EHA) 2026 Congress. We presented five scientific abstracts showcasing new translational insights into Pepaxti's dual nuclear and mitochondrial DNA-damaging mechanism, biomarker predictive tools for immunocompromised patients, and real-world safety data. We also hosted a well-attended PDC symposium with seven top experts from our key markets speaking about the evolving multiple myeloma landscape, clinical experience and the positioning of Pepaxti. This scientific credibility was further reinforced by the peer-reviewed publication of our Phase 2 BRIDGE study in Clinical Lymphoma, Myeloma and Leukemia, validating the safe and effective use of an optimized 30 mg dose of Pepaxti in patients with moderate renal impairment—a fragile patient segment representing roughly 50 percent of all multiple myeloma diagnoses.

Beyond multiple myeloma, our brain cancer program entered active clinical evaluation following swift Norwegian regulatory approval and the first patient enrolled in our glioblastoma "Window-of-Opportunity" study at Oslo University Hospital. Using an approved PDC probe in approximately 10 surgical patients, this lean study evaluates safety and blood-brain barrier penetration. The first patient in the study has been dosed and based on an assessment by the safety review committee recruitment of further patients has been initiated. The global glioblastoma market is expected to exceed USD 8 billion by 2035 and represents a profound unmet medical need. Oncopeptides' PDC molecules are believed to be uniquely equipped to pass the blood-brain barrier due to their small size and lipophilicity, entering the target cancer cells freely to deliver their cytotoxic payload directly where it is needed.

We enter the second half of 2026 with maintained focus on our commercialization, deepening clinical evidence, the potential for a transformative regulatory milestone in Europe, and progression of our pipeline.

Stockholm, August 27, 2026

Sofia Heigis
CEO

Financial Overview

REVENUE
Net sales of Pepaxti during the quarter were SEK 31.1 (19.2) million and for the six-month period SEK 56.5 (32,5) million. The turnover for the period refers to Europe only.

GROSS PROFIT
Gross profit during the quarter were SEK 30.1 (18.8) million and for the six-month period SEK 55.2 (32.1) million.

OPERATING EXPENSES
Operating expenses during the quarter were SEK 78.8 (75.0) million and for the six-month period SEK 141.4 (148.2) million.

RESEARCH AND DEVELOPMENT EXPENSES
Research and development costs during the quarter were SEK 23.6 (21.0) million and for the six-month period SEK 45.0 (49.8) million Focus is on advancement of our pipeline with the window of opportunity study for Glioblastoma.

MARKETING AND SALES EXPENSES
Marketing and sales costs during the quarter were SEK 40.8 (36.6) million and for the six-month period SEK 71.9 (65.1) million. The increased costs relate to ongoing commercialization activities in Europe, focusing on Germany, Spain and Italy.

GENERAL AND ADMINISTRATIVE EXPENSES
Administrative costs during the quarter were SEK 16.7 (18.6) million and for the six-month period SEK 25.9 (35.4) million.

EXPENSES FOR SHARE BASED INCENTIVE PROGRAMS
For the six-month period, costs, including social security contributions, for share-related incentive programs amounted to SEK 2.8 (2.4) million. The cost does not affect cash flow in the period. See note 8.

TAX AND EARNINGS
Result during the quarter were SEK -54.7 (-62.8) million and for the six-month period SEK -87.0 (-123.5) million. This corresponds to earnings per share for the quarter of SEK -0.14 (-0.30) and for the six-month period SEK -0.27 (-0.58).

CASH FLOW, INVESTMENTS AND FINANCIAL POSITION
Cash flow from operating activities for the six-month period amounted to SEK -88.4 (-122.7) million. In March the company conducted a rights issue fueling liquidity with SEK 167 million after issue related cost. Equity in the group amounted to SEK 25.0 (-66.9) million at the end of the period. Equity for the parent company amounted to SEK 457.1 (386.9) million.

RIGHTS ISSUE 2026
On February 19, the company announced that the board of directors had decided to carry out a guaranteed new share issue of approximately MSEK 200 (guaranteed up to MSEK 190 including subscription commitments from the company's largest owner and its board and management) with preferential rights for the company's existing ordinary shareholders based on the authorization from the annual general meeting on May 22, 2025, with the support of the company's largest shareholder and management. The purpose of the rights issue is primarily to finance the ongoing commercialization of Pepaxti® in Europe until the commercial part of the company expects to have a positive cash flow in 2027, as well as a targeted development of the company's project for the indication Glioblastoma into clinical phase. The outcome of the rights issue was announced on March 17 resulting in a capital injection after issue related cost of SEK 167 million.

EMPLOYEES
At the end of the quarter, number of employees amounted to 69 (75).

PARENT COMPANY
The operations of the parent company correspond in all essential respects with the operations of the group, which is why the comments for the group also apply to the parent company.

ONCOPEPTIDES SHARE
At the end of the period, the number of registered shares eligible for trading and votes in Oncopeptides amounted to 395,287,003 inclusive of 14,138,885 C-shares held by the company.

AUDITOR REVIEW
This report has not been reviewed by the company's auditors.

Signatures

The Board and the CEO confirm that the interim report provides a true and fair reflection of the Group's and the Parent Company's operations, position and earnings and describes the material risks and uncertainty factors faced by the Parent Company and the companies within the Group.

Stockholm, August 27, 2026

Per Wold-Olsen
Chairman

Sofia Heigis
CEO

Christine Rankin
Board member

Per Samuelsson
Board member

Brian Stuglik
Board member

Condensed consolidated statement of comprehensive income

(SEK thousand)	Note	2026 apr-jun	2025 apr-jun	2026 jan-jun	2025 jan-jun	2025 jan-dec
Net sales	5	31 099	19 183	56 483	32 449	71 118
Cost of Goods Sold		-966	-395	-1 285	-310	-2 451
Gross profit		**30 133**	**18 788**	**55 197**	**32 139**	**68 667**
Research and development expenses		-23 533	-21 047	-45 027	-49 774	-102 970
Marketing and distribution expenses		-40 818	-36 593	-71 904	-65 081	-137 183
Administrative expenses		-16 739	-18 630	-29 926	-35 441	-57 439
Other operating income/expenses		2 289	1 248	5 461	2 089	4 274
Total operating expense		**-78 801**	**-75 021**	**-141 396**	**-148 208**	**-293 318**
EBIT; Operating profit/loss		**-48 668**	**-56 233**	**-86 199**	**-116 069**	**-224 651**
Net financial items		-5 936	-6 568	-467	-7 355	-23 519
EBT; Earnings before taxes		**-54 603**	**-62 801**	**-86 665**	**-123 424**	**-248 169**
Income tax		-108	-48	-231	-94	-1 415
Net profit		**-54 712**	**-62 849**	**-86 897**	**-123 518**	**-249 585**
Other comprehensive income						
Items to be reclassified as profit or loss						
Translation variances		95	169	-409	-179	-367
Other comprehensive income after tax		**95**	**169**	**-409**	**-179**	**-367**
Total comprehensive income attributable to Parent Company's shareholders.		**-54 616**	**-62 680**	**-87 305**	**-123 696**	**-249 952**
Earnings per share before/after dilution (SEK)		**-0,14**	**-0,30**	**-0,27**	**-0,58**	**-1,10**

Condensed consolidated statement of financial position

TSEK	Note	2026-06-30	2025-06-30	2025-12-31
Assets				
Tangible assets		13 361	22 343	17 682
Financial assets		-	-	-
Total non-current assets		**13 361**	**22 343**	**17 682**
Current assets				
Inventory		11 785	7 095	8 244
Current receivables		39 253	36 857	26 660
Cash		157 614	70 146	82 255
Total current assets		**208 651**	**114 098**	**117 159**
Total assets		**222 012**	**136 441**	**134 841**
Equity and liabilities				
Equity		24 927	-66 876	-58 891
Total equity		**24 927**	**-66 876**	**-58 891**
Long term liabilities				
Loans from credit institutions	6	135 173	124 230	126 681
Other long term liabilities		6 700	12 785	22 547
Total long-term liabilities		**141 873**	**137 015**	**149 228**
Current liabilities				
Trade payables		16 780	7 668	701
Other curren liabilities		38 432	58 635	43 803
Total current liabilities		**55 212**	**66 303**	**44 504**
Total equity and liabilities		**222 012**	**136 441**	**134 841**

Condensed consolidated statement of changes in equity

SEK Thousand	2026 apr-jun	2025 apr-jun	2026 jan-jun	2025 jan-jun	2025 jan-dec
Opening balance	**76 785**	**-5 843**	**-58 891**	**54 285**	**54 285**
Net profit	-54 712	-62 849	-86 897	-123 518	-249 585
Other comprehensive income	95	169	-409	-179	-367
Total comprehensive income	**-54 616**	**-62 680**	**-87 305**	**-123 696**	**-249 952**
Transaction with owners					
New issue of shares	0	0	190 000	0	150 232
Cost related to share issue	0	0	-23 131	0	-17 347
Share based compensation	2 758	1 647	4 254	2 535	3 890
Total transactions with owners	**2 758**	**1 647**	**171 123**	**2 535**	**136 776**
Ending balance	**24 927**	**-66 876**	**24 927**	**-66 876**	**-58 891**

Condensed consolidated statement of cash flow

SEK Thousand	2026 apr-jun	2025 apr-jun	2026 jan-jun	2025 jan-jun	2025 jan-dec
Operating activities					
Operating profit/loss	-48 668	-56 234	-86 199	-116 069	-224 651
Adjustment for non-cash items	4 936	6 179	7 654	-3 023	-13 770
Interest received	609	4	828	15	1 671
Interest paid	-1 409	0	-3 542	0	0
Taxes paid	30	40	19	0	-114
Cash-flow from operating activities before change in working capital	**-44 502**	**-50 011**	**-81 240**	**-119 077**	**-236 864**
Change in working capital	1 691	-4 400	-7 163	-3 651	20 371
Cash-flow from operating activities	**-42 811**	**-54 411**	**-88 403**	**-122 728**	**-216 493**
Cash-flow from investment activities	0	0	0	0	0
Cash-flow from financing activities	-4 761	17 961	165 403	15 922	122 163
Cash-flow for the period	**-47 572**	**-36 450**	**77 000**	**-106 806**	**-94 330**
Cash at the beginning of the period	205 154	107 225	82 256	178 536	178 536
Change in cash	-47 572	-36 450	77 000	-106 806	-94 331
Effect of exchange rate changes on cash	32	-630	-1 642	-1 585	-1 951
Cash at the end of the period	**157 614**	**70 146**	**157 614**	**70 146**	**82 255**

Condensed Parent Company income statement

(SEK thousand)	Note	2026 apr-jun	2025 apr-jun	2026 jan-jun	2025 jan-jun	2025 jan-dec
Net sales	5	31 099	19 183	56 483	32 449	71 118
Cost of Goods Sold		-966	-395	-1 285	-310	-2 451
Gross profit		**30 133**	**18 788**	**55 197**	**32 139**	**68 667**
Research and development expenses		-23 583	-24 886	-45 136	-56 450	-103 218
Marketing and distribution expenses		-41 985	-37 701	-74 141	-67 042	-141 003
Administrative expenses		-24 331	-18 674	-41 318	-35 527	-71 491
Other operating income/expenses		2 383	2 300	5 406	6 755	10 890
Total operating expense		**-87 515**	**-78 961**	**-155 190**	**-152 264**	**-304 822**
EBIT; Operating profit/loss		**-57 382**	**-60 173**	**-99 992**	**-120 125**	**-236 155**
Net financial items		-5 869	-935	-289	4 547	-255
Earnings after net financial items		**-63 251**	**-61 108**	**-100 282**	**-115 578**	**-236 410**
Group contribution		0	-12 047	0	-27 552	-41 591
EBT; Earnings before taxes		**-63 251**	**-73 155**	**-100 282**	**-143 129**	**-278 001**
Tax		0	0	0	0	0
Net profit		**-63 251**	**-73 155**	**-100 282**	**-143 129**	**-278 001**

Condensed Parent Company statement of comprehensive income

SEK thousand	2026 apr-jun	2025 apr-jun	2026 jan-jun	2025 jan-jun	2025 jan-dec
EBT; Earnings before taxes	-63 251	-73 155	-100 282	-143 129	-278 001
Other comprehensive income	-	-	-	-	-
Net profits	**-63 251**	**-73 155**	**-100 282**	**-143 129**	**-278 001**

Condensed Parent Company balance sheet

SEK thousand	Note	2026-06-30	2025-06-30	2025-12-31
Assets				
Tangible assets		3 122	4 809	3 783
Financial assets		510 745	500 445	510 745
Total non-current assets		**513 867**	**505 254**	**514 528**
Current assets				
Inventory		11 785	7 095	8 244
Current receivables		103 509	96 088	97 400
Cash		144 225	62 100	74 859
Total current assets		**259 519**	**165 284**	**180 503**
Total assets		**773 386**	**670 538**	**695 031**
Equity and liabilities				
Restricted equity		54 130	35 293	40 509
Non-restricted capital		402 989	351 616	345 767
Total Equity		**457 118**	**386 909**	**386 277**
Long term liabilities				
Loans from credit institutions	6	135 173	124 230	126 198
Long-term liabilities		5 710	3 931	18 046
Total long-term liabilities		**140 883**	**128 161**	**144 245**
Current liabilities				
Trade payables		15 177	6 179	0
Other current liabilities		160 207	149 289	164 510
Total current liabilities		**175 385**	**155 468**	**164 510**
Total equity and liabilities		**773 386**	**670 538**	**695 031**

NOTE 1 - GENERAL INFORMATION

This interim report covers the Swedish parent company Oncopeptides AB (publ), registration number 556596-6438, as well as the wholly owned subsidiaries Oncopeptides Incentive AB, Oncopeptides Innovation AB (with the wholly owned subsidiary Oncopeptides Innovation 1 AB), Oncopeptides GmbH and Oncopeptides Srl and Oncopeptides SL. The parent company is a public limited company based in Stockholm. The figures in brackets in the report refer to the corresponding period of the previous year. The interim report has been approved for publication on August 27, 2026.

NOTE 2 - ACCOUNTING PRINCIPLES

The group's interim report is prepared in accordance with IAS 34. The parent company applies the Swedish Financial Reporting Council's recommendation RFR 2. Oncopeptides applies, other than what appears below, the same accounting principles as in the most recent annual report. Significant accounting and valuation principles can be found on pages 43-48 of the annual report for 2025. No new or changed standards have been introduced since 1 January 2026 that have had any significant impact on the company's financial reporting.

Oncopeptides applies ESMA's (European Securities and Markets Authority) guidelines for alternative key figures.

NOTE 3 - RISKS AND UNCERTAINTIES

In its operations, Oncopeptides is exposed to a number of risks. The company continuously evaluates known and predictable risks and acts to minimize the effect of these risks within the framework of the company's business strategy and safeguarding the company's long-term interests, including its sustainability. The company assesses that the risks described in the annual report for 2025 remain during the period.

NOTE 4 - ESTIMATES AND CONSIDERATIONS

This report contains forward-looking statements. Actual results may differ from those stated. Internal factors such as successful management of research programs and intellectual property rights may affect future results. The interim report has been prepared with the assumption that the company has the ability to continue operations during the next 12-month period, in line with the going concern principle.

NOTE 5 - REVENUE RECOGNITION

There has been no change in the principle of revenue recognition compared to the annual report 2025. Revenue is recognized at the transaction price for goods sold excluding value added tax, but including discounts. Revenue is recognized at the time of delivery when Oncopeptides has fulfilled its performance commitment and control of the goods passes to the customer.

The customers are defined as hospitals and/or clinics and retailers who sell the goods to the final user of the goods. As the final price is related to the discount that applies in the respective local market the parent company and the group report a liability for a calculated discount based on the frameworks for discounts that apply in each market. The provision for estimated discounts is reported under the heading Other short-term liabilities in the balance sheet.

Parent company revenue	2026	2025	2026	2025	2025
SEK thousand	apr-jun	apr-jun	jan-jun	jan-jun	jan-dec
Goods	31 099	19 183	56 483	32 449	71 118
Total net revenue	**31 099**	**19 183**	**56 483**	**32 449**	**71 118**
Geographical market					
Europe	31 099	19 183	56 483	32 449	71 118
Summa	**31 099**	**19 183**	**56 483**	**32 449**	**71 118**

NOTE 6 – LOANS FROM CREDIT INSTITUTIONS

The liability relates to a loan from EIB in EURO. It will not be amortized until the 16th of June 2028, when it will be fully repaid. The interest is accumulated and capitalized during the term and paid in connection to the repayment of the loan. The contractual interest rate is 7% for the full term. The effective interest rate is estimated at 10.8%, including arrangement costs and the initial market value of the transferred warrants allocated during the term of the loan.

In connection to the signing of the agreement, an issue of warrants was performed, whereof 3 383 326 warrants representing 1.26% of outstanding shares after dilution has been transferred to EIB without compensation. As of end year-end 2025 the company has no longer the ability draw additional tranches on the loan.

EIB has the right to exercise the warrants and subscribe for shares at the quota value. The warrants may be exercised at any time for a period of 20 years, in full or in part, by the warrant holder.

EIB has the right, under certain circumstances and in connection to the repayment of the loan, to demand that Oncopeptides acquire the warrants at fair value in a situation when it is not possible to transfer the warrants to a third party.

NOTE 7 - RELATED PARTY TRANSACTIONS

Remuneration to senior management has been paid in accordance with current policies. No other transactions with related parties, outside of the Oncopeptides Group, occurred during the period.

NOTE 8 - SHARE BASED INCENTIVE PROGRAMS

The purpose of share-based incentive programs is to promote the company's long-term interests by motivating and rewarding the company's senior management, founders, and other co-workers in line with the interest of the shareholders. Oncopeptides has currently ten programs that include the management team, certain Board members, founders and employees.

Program
- 2018; "Co-worker LTIP 2018"
- 2019; "Co-worker LTIP 2019"
- 2022; "Co-worker LTIP 2022" and "Board SHP 2022"
- 2023; "Board SHP 2023"
- 2024; "Co-worker LTIP 2024" and "Board SHP 2024"
- 2025; "Board SHP 2025"
- 2026; "Co-worker LTIP 2026" and "Board SHP 2026"

For more information on the programs see Note 26 in the Annual report 2025 as well as Agendas and Minutes from the relevant Annual General Meetings on the company's website www.oncopeptides.com.

At the end of the period, full utilization (including warrants for securing social security contributions but excluding warrants related to EIB), of
- Options and share awards resolved by the AGM and awarded to named individuals corresponding to 14,188,892 shares, would result in a dilution of 5,1 percent (including hedge for social charges).
- Options and share awards resolved by the AGM and awarded to named individuals as well as those not yet awarded to individuals, corresponding to 19,725,184 shares, would result in a dilution of 6.8 percent (including hedge for social charges).

NOTE 9 - SIGNIFICANT EVENTS AFTER THE PERIOD

No significant events occurred after the end of the period other than as mentioned in the report.

Key performance measures

In this report, certain key performance measures are presented, including measures that are not defined under IFRS,

- Research and development / operating expenses, %,
- Gross margin, TSEK, %.

The company believes that these measurements provides valuable additional information when evaluating the company's economic trends. These financial performance measures should not be viewed in isolation, nor be considered in replacement of performance indicators that are prepared in accordance with IFRS.

Further, such performance measures, as the company has defined them, should not be compared with other performance measures with similar names used by other companies since definitions and calculation methods may vary between companies.

SEK, Thousand	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2025 Jan-Dec
Net sales	31 099	19 183	56 483	32 449	71 118
Gross profit[1]	30 133	18 788	55 197	32 139	68 667
Gross margin[2]	97%	98%	98%	99%	97%
Registered common shares outstanding					
beginning of period	381 148 118	211 263 903	258 567 472	211 263 903	211 263 903
end of period	381 357 758	211 263 903	381 357 758	211 263 903	258 567 472
C-shares for LTI programs[3]	13 929 245	14 494 920	13 929 245	14 494 920	14 138 885
Registered shares; end of period including C-shares	395 287 003	225 758 823	395 287 003	225 758 823	272 706 357
Share capital at the end of period	43 921	23 910	43 921	23 910	30 301
Equity at the end of period	24 927	-66 876	-58 891	-66 876	-58 891
Earnings per share before/after dilution, kr[4]	-0,14	-0,30	-0,27	-0,58	-1,10
Operating loss	-48 668	-56 233	-86 199	-116 069	-224 651
Research and development expenses	-23 533	-21 047	-45 027	-49 774	-102 970
R&D costs/operating expenses, %[5]	30%	28%	32%	34%	35%

1) Defined by subtracting cost of goods sold from total sales. The key figure shows gross profitability of cost of goods sold in absolute numbers.
2) Defined by dividing the sum of the company's gross profit by total sales. The key figure aims to clarify the relative profitability of goods sold.
3) For more information, please see the notice to the Annual General Meeting 2026.
4) Earnings per share before dilution are calculated by dividing earnings attributable to shareholders of the Parent Company by a weighted average number of outstanding shares during the period. There is no dilution effect driven by the employee stock option program, as earnings for the periods have been negative.
5) Defined by dividing the research and development costs with total operating expenses. The key performance measure provides an indication of the proportion of expenses that are attributable to the company's core business.

Telephone conference

The interim report for the period and an operational update will be presented by CEO Sofia Heigis and members of Oncopeptides Leadership team, Thursday August 27, 2026, at 09:00 (CET).

If you wish to participate via **webcast**, please use the link below. Through the webcast you can ask written questions.
https://oncopeptides.events.inderes.com/q2-report-2026

If you wish to participate via **telephone conference**, please register on the link below. After registration you will be provided a phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.

https://events.inderes.com/oncopeptides/q2-report-2026/dial-in

Financial Calendar

Report	Date
Interim report Q3 2026	5 November 2026

Contact

Oncopeptides AB
Visiting address; Luntmakargatan 46, 111 37 Stockholm
Domicile: Luntmakargatan 46, 111 37 Stockholm, Sweden

Telephone: +46 8 615 20 40
E-mail: info@oncopeptides.com

Website: oncopeptides.com

Thesaurus

EMA	European Medicines Agency Europeiska läkemedelsmyndigheten
CHMP	The European Medicines Agency's Committee for Medicinal Products for Human Use Europeiska läkemedelsmyndighetens kommitté för humanläkemedel